Dear ,

In the current issue of the OncoWuXi Newsletter, we would like to share with you our NanoString platform for research and translational applications. Other interesting topics covered in this issue include the recent developments in WuXi AppTec in vitro immunology platform, and VEGF-VEGFR related in vivo models.

OncoWuXi Newsletter will continue to keep you up-to-date with our recent progress in cancer research. As part of WuXi Research Service Division (RSD), our topnotch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.

Translational Oncology
NanoString Platform for Research and Translational Applications
(1)  Introduction of NanoString technology
  • Principle and highlights

(2)  Introduction of NanoString services scope

(3)  Workflow and procedure of NanoString analysis

(4)  In house validation of NanoString analysis
  • Sensitivity, reproducibility, and dynamic range

(5)  Application of NanoString technology
  • Identification of differentially expressed genes in tumor and paracancer tissues
  • Identification of CT antigen
  • T cell function gene set analysis
  • Cell type profiling
  • Functional enrichment analysis

(6)  Introduction of NanoString panels
  • Commercial and customized panels

(7)  Case studies
  • Exploration on responses of animal models to anti-tumor drugs at transcriptional level
  • Time-ordered immune responses assessment in syngeneic tumor model after treatment

WuXi AppTec In Vitro Immunology Platform
(1) T cell activation by antibody/SEB/PHA/CMV recall

(2) B cell activation

(3) NK cell activation/expansion

(4) T cell polarization: Th1, Th2, Th17 and Treg

(5) M1 and M2 macrophage differentiation

(6) DC differentiation

(7) CTL cytotoxicity assay: OT-1 T cell-OVA system/CAR T cell system

(8) NK cytotoxicity assay using NK-92MI cells

(9) ADCC assay using purified primary NK cells, ADCP assay using macrophages differentiated from purified primary CD14+ monocytes, and CDC assay 

(10) Mixed lymphocyte reaction: DC-T cell co-culture

(11) MDSC suppressive assay: MDSC-T cell co-culture

(12) Treg suppressive assay: Treg-Teff cell co-culture

(13) Tumor cell suppressive assay: Hela-T cell co-culture

(14) STING pathway activation

(15) NLRP3 inflammasome activation

(16) Antigen specific T cell activation in vivo (OT-1 system)

Targeted Oncology
VEGF-VEGFR Related In Vivo Models
(1)  Background of VEGF-VEGFR as drug targets
  • VEGF-VEGFR biology
  • Summary of VEGF-VEGFR inhibitors

(2)  VEGF-VEGFR related CDX models
  • HCT-15, SW620, LS174T, and HT-29 colorectal cancer CDX models, validated with Avastin or Regorafenib
  • Huh7, BEL-7404, Hep-3B and JHH-7 liver cancer CDX models, validated with Avastin and Sorafenib
  • Calu-6, A549, NCI-H520, PC-9, and NCI-H358 NSCLC CDX models, validated with Nintedanib, Axitinib, Sunitinib, Apatinib or Avastin
  • 786-O and ACHN renal cancer CDX models, validated with Sorafenib, Sunitinib and Avastin
  • MCF-7 breast cancer and U87MG glioblastoma CDX models, validated with Avastin
  • NCI-H69 SCLC CDX model, validated with Anlotinib
  • MKN-45 gastric cancer CDX model, validated with Sunitinib and Apatinib
  • FTC-238 thyroid cancer CDX model, validated with Lenvatinib

(3)  VEGF-VEGFR related PDX models
  • 25 HCC PDX models, validated with Sorafenib, Regorafenib, Lenvatinib or other TKIs
  • 8 cholangiocarcinoma PDX models, validated with Cabozantinib
  • Other PDX models, validated with Sorafenib, Avastin, Cabozantinib or Pazopanib

We sincerely appreciate your interest, time and support, and would like to hear your feedback so we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns.

Best regards,
WuXi AppTec OncoWuXi Team